X

Drug Profile

Ketoconazole foam - Stiefel Laboratories

Alternative Names: 2% Ketoconazole foam - Stiefel Laboratories; Extina

Latest Information Update: 07 Jan 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stiefel Laboratories
Class Antifungals; Azoles; Piperazines; Small molecules
Mechanism of Action 14-alpha demethylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Seborrhoeic dermatitis
Discontinued Mycoses

Most Recent Events

30 Aug 2011 First generic equivalent approved in the US for the topical treatment of seborrhoeic dermatitis in immunocompetent patients 12 years of age and older
22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
12 Jul 2007 Registered for Seborrhoeic dermatitis in USA (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com